Xifaxan rifaximin: Phase II data

Data from an active-controlled, U.S. Phase II trial in 27 patients showed that 400 mg twice-daily oral Xifaxan led to response in 11 of 13 patients compared to 13 of 14 patients receiving 40-60 mg dai...